Joy Mootien

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020

Charlotte Kaeuffer, Coralie Le Hyaric, Thibaut Fabacher et al. · Eurosurveillance · 2020 · 128 citations · Full text

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy et al. · Clinical Microbiology and Infection · 2021 · 102 citations · Full text

Clinical Infectious Disease, Open-label Randomized, Antiviral Drug Development +6

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Trøseid, José Ramón Arribas, Lambert Assoumou et al. · Critical Care · 2023 · 46 citations · Full text

Clinical usefulness of 18 F–FDG PET/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis

Nicolas Lefèbvre, Xavier Argemi, Nicolás Meyer et al. · Nuclear Medicine and Biology · 2017 · 40 citations

F–fdg Pet/ct, Pulmonary Tuberculosis, Initial Staging +8